This finding suggests that TJC4 plus Venetoclax is a promising therapeutic, while inhibiting BCL-2 and CD47 may represent a new treatment mode for B-cell NHL patients [112]. This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.